Group 1 - Market volatility has increased recently due to fears of AI disruption affecting various sectors, including insurance brokers, wealth management firms, and commercial real estate services [2] - Bitcoin continues to trade below the $70,000 level after previously surpassing it, indicating ongoing market uncertainty [2] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [2] Group 2 - The analyst has a beneficial long position in AMZN shares, indicating confidence in the stock's performance [3] - Seeking Alpha emphasizes that past performance does not guarantee future results, highlighting the inherent risks in investment [4]

Core Viewpoint - Vistagen Therapeutics is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the efficacy of its drug fasedienol, leading to significant financial losses for investors [1][1]. Group 1: Legal Proceedings - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics and has set a deadline of March 16, 2026, for investors to seek the role of lead plaintiff in the class action [1]. - The lawsuit claims that Vistagen and its executives violated federal securities laws by failing to disclose material adverse facts about the drug fasedienol's trial results [1][1]. - Following the announcement of the failed PALISADE-3 clinical trial results, Vistagen's stock price plummeted over 81%, opening at $0.88 per share [1][1]. Group 2: Clinical Trial Results - On December 17, 2025, Vistagen reported that its PALISADE-3 study did not meet its primary efficacy endpoint, failing to show statistically significant improvement in reducing anxiety compared to placebo [1][1]. - The positive assertions made by Vistagen regarding fasedienol's future trial success were deemed false and misleading, contributing to the inflated stock prices prior to the announcement [1][1]. Group 3: Investor Information - Investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, are encouraged to contact Faruqi & Faruqi for discussions regarding their legal rights [1][1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [1][1].

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is among the Most Volatile Stocks. On February 6, 2026, TD Cowen upgraded Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s price target to $21 from $20 while keeping a Buy rating, citing a Q4 beat and an improved outlook. TD Cowen said that community adoption, new indications, pharma guidelines, EMR integrations, and a shift to blood-based testing were major driving factors. On February 6, 2026, BTIG maintained a Buy rating on Adaptive Biotechnologi ...

Core Insights - Abivax has presented new preclinical and clinical data for obefazimod, demonstrating its anti-fibrotic potential and favorable safety profile for treating inflammatory bowel disease at ECCO 2026 [2][3] Group 1: Clinical Data and Efficacy - The data presented includes evidence of obefazimod's anti-fibrotic effects in both preclinical human fibroblast models and in vivo animal models, indicating its potential to address unmet needs in Crohn's disease [4] - A pooled analysis from the Phase 3 ABTECT induction trials shows that obefazimod leads to symptomatic response as early as week 1 and symptomatic remission by week 2, with a nominally significant p-value of <0.05 [4][5] - Obefazimod demonstrated a ~50% reduction in a biomarker of active fibrosis (Pro-C3) and a ~30% reduction in a fibroblast activation marker (⍺SMA) in preclinical models, both with p-values <0.0001 [5] Group 2: Safety Profile - The safety data from the ABTECT-1 and ABTECT-2 trials indicate that the rates of serious treatment emergent adverse events (TEAEs) were comparable across treatment groups, with Obe-50mg at 3.1%, Obe-25mg at 2.2%, and placebo at 3.2% [8] - TEAEs leading to study discontinuation were also similar across groups, with Obe-50mg at 4.7%, Obe-25mg at 1.9%, and placebo at 4.1% [8] Group 3: Mechanism of Action - Biomarker data from the trials indicate that obefazimod enhances the expression of miR-124 and reduces key inflammatory cytokines IL-17A and IL-6 towards homeostatic levels, supporting its mechanism of action in restoring immune balance [4][8] - The mechanism allows for partial reduction of inflammatory cytokines without completely blocking these pathways, which may be beneficial for long-term disease management [8]

Core Viewpoint - Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company regarding its clinical studies [1]. Group 1: Class Action Details - The class action pertains to Mereo ADSs purchased between June 5, 2023, and December 26, 2025, with a lead plaintiff deadline set for April 6, 2026 [1]. - Investors who purchased Mereo ADSs during the specified period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][7]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by the April 6, 2026 deadline [3]. Group 3: Case Background - The lawsuit claims that Mereo BioPharma provided investors with optimistic statements regarding the Phase 3 Orbit and COSMIC studies for setrusumab in treating Osteogenesis Imperfecta (OI), suggesting confidence in the drug's efficacy [5]. - However, the defendants allegedly concealed material adverse facts, as neither study achieved its primary endpoints, leading to artificially inflated prices for Mereo's ADSs [6].

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”), of the important  April 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA ...

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2026. SO WHAT: If you purchased REGENXBIO securities during the Class Period you may be enti ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Much like the Internet Boom of the late 1990s, the rally in the market from 2023 to 2025 was primarily driven by the technology sector riding the wave of a new paradigm shift. At the end ofBret Jensen has over 13 years as a market analy ...

DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of $15,000,000, based on Nasdaq’s review of the ...

PresentationYigal NochomovitzCitigroup Inc., Research Division All right. Okay. Great. Thank you. I'm Yigal Nochomovitz, biotech analyst here at Citi in New York. This is the second day of our Virtual Oncology Summit. It's my pleasure to have with me from Zai Lab, Rafael Amado, who is the Head of Research and Development at the company. So welcome, Rafael. Thank you for doing this. For those listening, if you have questions for the company, just e-mail me and then I can relay those over to Rafael. So maybe ...